Abstract
Background
Lateral flow device (LFD) viral antigen immunoassays have been developed around the world as diagnostic tests for SARS-CoV-2 infection. They have been proposed to deliver an infrastructure-light, cost-economical solution giving results within half an hour.
Methods
LFDs were initially reviewed by a Department of Health and Social Care team, part of the UK government, from which 64 were selected for further evaluation from 1st August to 15th December 2020. Standardised laboratory evaluations, and for those that met the published criteria, field testing in the Falcon-C19 research study and UK pilots were performed (UK COVID-19 testing centres, hospital, schools, armed forces).
Findings
4/64 LFDs so far have desirable performance characteristics (orient Gene, Deepblue, Abbott and Innova SARS-CoV-2 Antigen Rapid Qualitative Test). All these LFDs have a viral antigen detection of >90% at 100,000 RNA copies/ml. 8951 Innova LFD tests were performed with a kit failure rate of 5.6% (502/8951, 95% CI: 5.1–6.1), false positive rate of 0.32% (22/6954, 95% CI: 0.20–0.48). Viral antigen detection/sensitivity across the sampling cohort when performed by laboratory scientists was 78.8% (156/198, 95% CI 72.4–84.3).
Interpretation
Our results suggest LFDs have promising performance characteristics for mass population testing and can be used to identify infectious positive individuals. The Innova LFD shows good viral antigen detection/sensitivity with excellent specificity, although kit failure rates and the impact of training are potential issues. These results support the expanded evaluation of LFDs, and assessment of greater access to testing on COVID-19 transmission.
Funding
Department of Health and Social Care. University of Oxford. Public Health England Porton Down, Manchester University NHS Foundation Trust, National Institute of Health Research.
【저자키워드】 COVID-19, public health, SARS-CoV-2, coronavirus, lateral flow, Testing, Viral antigen detection, United Kingdom, Lateral flow tests, LFD, National evaluation, Lateralflow devices, 【초록키워드】 SARS-COV-2 infection, hospital, diagnostic test, Test, Laboratory, Antigen, RNA, immunoassay, specificity, Cohort, Schools, COVID-19 testing, Characteristics, Research, Rapid, Qualitative, Trust, university, funding, COVID-19 transmission, criteria, Abbott, Support, NHS, Viral antigen, 95% CI, foundation, finding, Department, Public Health England, positive individuals, false positive rate, UK Government, greater, selected, identify, performed, can be used, Lateral, University of Oxford, 【제목키워드】 Sensitivity and specificity, Rapid, antigen detection, National,